Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating IncomePreferred Dividend PaymentsProfit After TaxRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

cbdMD (YCBD) Cost of Revenue (2016 - 2025)

cbdMD's Cost of Revenue history spans 10 years, with the latest figure at $2.0 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 17.67% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 1.94% increase, with the full-year FY2025 number at $7.2 million, down 3.53% from a year prior.
  • Cost of Revenue hit $2.0 million in Q4 2025 for cbdMD, up from $1.9 million in the prior quarter.
  • Over the last five years, Cost of Revenue for YCBD hit a ceiling of $4.3 million in Q4 2021 and a floor of $1.7 million in Q4 2024.
  • Historically, Cost of Revenue has averaged $2.5 million across 5 years, with a median of $2.2 million in 2023.
  • Biggest five-year swings in Cost of Revenue: surged 33.35% in 2021 and later tumbled 41.84% in 2022.
  • Tracing YCBD's Cost of Revenue over 5 years: stood at $4.3 million in 2021, then tumbled by 41.84% to $2.5 million in 2022, then fell by 27.79% to $1.8 million in 2023, then dropped by 5.78% to $1.7 million in 2024, then rose by 17.67% to $2.0 million in 2025.
  • Business Quant data shows Cost of Revenue for YCBD at $2.0 million in Q4 2025, $1.9 million in Q3 2025, and $1.8 million in Q2 2025.